GlassScriptPhysician profile
Mousumi Dey
NPI 1275954554
$1,005.01
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $157 · 2022: $618 · 2023: $201 · 2024: $29.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $230.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $246.44 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $135.46 | 2022 | |
| Emd Serono, INC. | $105.61 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $99.60 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.07 | 2022 | |
| Lilly USA, LLC | $52.02 | 2021-2022 | |
| Acorda Therapeutics, INC | $48.00 | 2022 | |
| Sk Life Science, INC. | $44.73 | 2022 | |
| Genzyme Corporation | $36.11 | 2022 | |
| Amgen INC. | $34.33 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $32.58 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $32.19 | 2022 | |
| Kyowa Kirin, INC. | $18.72 | 2021 | |
| Argenx US, INC. | $16.17 | 2022 | |
| Biogen, INC. | $15.13 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $13.46 | 2022 | |
| Amneal Pharmaceuticals LLC | $12.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mousumi Dey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.